Distribution of mEPHX genotypes in patients with COPD and healthy subjects
| Homozygous wild type | Heterozygous type |
Homozygous mutant type | |
| Exon 3 polymorphism2-150 | |||
| Control (n = 76) | 20 (26%) | 24 (32%) | 32 (42%) |
| COPD (n = 83) | 24 (29%) | 23 (28%) | 36 (43%) |
| OR (95% CI) | 1.0 | 0.80 (0.35 to 1.83) | 0.94 (0.44 to 2.01) |
| OR (95% CI) smoking adjusted | 1.0 | 0.86 (0.32 to 2.26) | 1.08 (0.46 to 2.56) |
| Exon 4 polymorphism† | |||
| Control (n = 76) | 57 (75%) | 17 (22%) | 2 (2%) |
| COPD (n = 83) | 59 (71%) | 16 (19%) | 8 (10%) |
| OR (95% CI) | 0.26 (0.06 to 1.16) | 0.30 (0.05 to 1.20) | 1.0 |
| OR (95% CI) smoking adjusted | (0.03 to 1.29) | 0.12 (0.01 to 1.57) | 1.0 |
↵2-150 p = 0.86, †p = 0.19 (χ2 test).
OR; odds ratio, 95% CI; 95% confidence interval.